Perhaps, but how do you congratulate yourself on a 5% revenue increase, when you have an extra week in the quarter? At least they were at the upper range of their guidance, which is certainly not what we often experience.
Smoked, it seems no matter what you post, you get thumbs down. I appreciate the information content in your posts.
"As of December 29, 2015 and December 30, 2014, we had no debt outstanding under our credit facility". Pea, as I understand it, they borrowed 60 mil during the year under the credit facility, and paid it back before year end. If you do a search of 10-k under "credit facility" it actually seems to show that and say that.
Pea, I did what you directed and of course found what you did. However, if you look at the balance sheet, even on yahoo for Dec 2015, or in the 10-k, there does not seem to be either short term/current or long term debt.
They go on a lot, since stock options are a big part of compensation. Driscoll sold 4800 shares at $17.20 in the past few days. I would have thought that since 10-Q has not been released, this would not be permitted.
Very upbeat after very good results. A strong suggestion they will raise guidance after 2nd quarter. Still 5 million in free cash flow for the year doesn't seem that great, and there is a suggestion that the shift in first aid requirements to ANSI 2015 is a short term help.
Thanks. For anyone else looking, click on the 2nd entry under Steel Partners in Edgar.
Note removal of postings by people shilling, apparently, for lawyers suing about buy out. At the same time,it is possible an auction would have garnered a higher price, but I have been skeptical the lawsuits will benefit anyone besides the lawyers.
RBC Capital Markets lowers its rating on Autoliv (NYSE:ALV) to Underperform.
The investment firm chops its price target on the automobile industry supplier to $96 which implies a 15% slide in share price.
Steve, when I tried to join investor village they wanted info that had me concerned. Do you get a lot of email from them or any other problems?
Interesting. You have just joined Yahoo message boards so this is your only post. Mr. Tedkov has been a member since July 2014, and his/her only other post, back when he joined, was about a lawsuit against another take over.
From a cursory look, it does not appear that Gabelli is a major shareholder of HNH. Hence, if he does not contest the offer, then I will have to think it is reasonable.
I wonder if any of us would have taken $34 offer more seriously, and possibly bought more stock, if not for the previous debacle. Big question: is Gabelli going to be satisfied, or has he already blessed the deal?
Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced that new data on patients at intermediate risk for open-heart surgery demonstrated that transcatheter aortic valve replacement (TAVR) with the SAPIEN 3 valve was superior to surgery at one year on a composite primary endpoint of mortality, stroke and moderate or severe aortic regurgitation. In addition, the SAPIEN 3 valve demonstrated clinical superiority at one year on individual assessments of all-cause mortality and of stroke.